Ibrutinib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AIFA (Italy), DMC (Denmark) and G-BA (Germany), among others, recommended or restricted ibrutinib, while AWMSG (Wales), CONITEC (Brazil) and ZIN (Netherlands) did not recommend it.
On the same population the two systems disagree outright: NICE (England) recorded restricted in TA502, while PBAC (Australia) recorded not recommended for “Relapsed or refractory mantle cell lymphoma”.
NYE METODER (Norway) has been harder on ibrutinib than on its own caseload: it refused 7 of 9 decisive submissions here (78%), against a base rate of 37% across everything it has assessed.
Assessment has run over 11.2 years, from 17 Jun 2015 at HAS (France) to 23 Sep 2026 at NICE (England).
CIPM (Spain) changed its position: not recommended on 6 May 2021, recommended by 20 May 2026, after a resubmission.
Every one of the eight highest-volume agencies in this archive has a record for ibrutinib.
Not every gap is a refusal: for ibrutinib, 5 submissions were never made and 6 were withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 28 of 108 records date from 2023 or later.
The programme is broad: 30 distinct indication wordings are recorded for ibrutinib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
20 of these 108 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess ibrutinib, on 17 Jun 2015; DMC (Denmark) did not open a file until 21 Jan 2026 — an unusually long tail of 10.6 years between the earliest and latest system to look at it.
The record arrives in waves: 12 separate years each carry two or more decisions, spread across 12 years in total.
14 of the 15 agencies here assessed ibrutinib more than once, PBAC (Australia) most often at 20 entries — repeat review is the norm for this molecule rather than the exception.
ibrutinib has been through 15 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for ibrutinib reads 30 recommended, 26 not recommended, 16 restricted and 7 other, with 29 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AWMSG (Wales) | 26 Aug 2026 | In combination with rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone (R-CHOP) for the treatment of ad… | excluded, NICE appraised | source |
| AIFA (Italy) | 19 Jul 2026 | IMBRUVICA in associazione con rituximab, ciclofosfamide, doxorubicina, vincristina e prednisolone (IMBRUVICA+ R-CHOP) al… | innovative · reimbursed class H | source |
| TLV (Sweden) | 24 Feb 2026 | Imbruvica ingår i högkostnadsskyddet med begränsning för ytterligare en patientgrupp | restricted subsidy | source |
| NYE METODER (Norway) | 21 Apr 2024 | Kombinasjonsbehandling i førstelinje med bendamustin og rituksimab til behandling av mantelcellelymfom (MCL) når autolog… | decision recorded | source |
| CIPM (Spain) | 6 May 2021 | Indicaciones terapéuticas autorizadas: Imbruvica en monoterapia está indicado para el tratamiento de pacientes adultos… | not financed by the SNS (financed 2026-05) | source |
103 further decisions for ibrutinib, across 15 agencies, are not shown here. They include the most recent record on file, 23 Sep 2026 from NICE (England); its outcome is in the subscriber dataset. They link to 73 further source documents.
Related molecules
- pirtobrutinib — divergent outcome (recommended vs not recommended) on a shared indication
- zanubrutinib — same ATC class L01E — Antineoplastics
- cabozantinib — same ATC class L01E — Antineoplastics
- selpercatinib — same ATC class L01E — Antineoplastics
- acalabrutinib — same ATC class L01E — Antineoplastics
- ribociclib — same ATC class L01E — Antineoplastics
Coverage: 108 decisions for ibrutinib from 15 agencies, 2015 to 2026. Data to 7 Sep 2026. ATC class L01E — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.